12-18

13-19

14-20

15-21

16-22

17-23

18-24

Authors

Year

Paper Title

Keywords

Ruoshuang Han, et al.

2024

Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.

Osimertinib, Drug resistance, Anti-angiogenesis, Tumor microenvironment

Stecklum, Maria, et al.

2024

Humanization of NOG mice and next generation NOG mouse strains

Humanized mice，CD34+HSC

Danny V. Jeyaraju, et al.

2024

Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase.

acute myeloid leukemia (AML) ,  leukemic stem cell (LSC) , azacitidine

Willis E, et al.

2024

Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation
phenotype relative to NSG-SGM3 mice

hemophagocytic lymphohistiocytosis, human hematopoietic stem cells, humanization, macrophage activation syndrome, mast cell hyperplasia, mouse, NOG-EXL, NSG-SGM3

Gutierrez-Barbosa H, et al.

2024

Evaluation of Four Humanized NOD-Derived Mouse Models for Dengue Virus-2 Infection.

 humanized mice; dengue; NSG; EXL; SGM3; NCG; CD34+; PBMCs

Caroline Mignard, et al.

2023

OncoTAM, a comprehensive preclinical platform to explore Macrophages as key drivers of cancer progression and develop new therapies against Tumor-Associated-Macrophages

Macrophage，huHSC-NOG-EXL, Breast xenograft, Lung xenograft

Chin A, et al.

2023

Preclinical Evaluation of Lintuzumab-Ac225, a CD33 Antibody Radioconjugate Targeting Myeloid-Derived Suppressor Cells

Lintuzumab-Ac225, CD33, Myeloid-derived suppressor cells (MDSCs), H1975, PET

Zev A. Binder, et al.

2023

Severely immunodeficient NOG-EXL mice allow for humanization and development of a human glioblastoma-derived tumor microenvironment

GBM organoids (GBOs), CD34+ hematopoietic stem cells, NOG-EXL,Macrophage activation score (MAS), hCD45+

Manni S, et al.

2023

Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies.

Chimeric antigen receptor T (CAR-T) cell ，CRS,  IFNγ，CD19+ lymphoma cells

Gutierrez-Barbosa H, et al.

2023

A Comparison of Lymphoid and Myeloid Cells Derived from Human Hematopoietic Stem Cells Xenografted into NOD-Derived Mouse Strains

humanization; humanized mouse model; xenograft; CD34; NOG-EXL; NSG-SGM3; lymphoid; myeloid

Jingping Yang, et al.

2023

AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors

Caruso, Simona et al.

2022

Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia

AML, CD123, cell therapy, CAR-NK, CAR-T, safety assessment

P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia

Koji Jimbo, et al.

2022

Genetic deletion and pharmacologic inhibition of E3 ubiquitin ligase HOIP impairs the propagation of myeloid leukemia

Daniel H. Albert, et al.

2022

Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML

Mivebresib, co-clinical PDX models, BRT inhibitors, AML

Ghoneim MA, et al.

2022

Transplantation of insulin-producing cells derived from human mesenchymal stromal/stem cells into diabetic humanized mice

Diabetes, insulin-producing cells (IPCs), adipose tissue-derived stem cells (hAT-MSCs), mesenchymal stromal cells,

Justin A. Kenkel, et al.

2022

Dectin-2 agonist antibodies reprogram tumor-associated macrophages to drive anti-tumor immunity

C.J. Little, et al.

2022

Robust engraftment of fetal nonhuman primate CD34-positive cells in immune-deficient mice

HSC engraftment, rhesus macaque hematopoietic tissues, NHPs, immune system reconstitution

Jamil Hauqe, et al.

2022

An ADCC enhanced anti-CCR8 antibody which preferencially depletes intratumoral regulatory T cells and inhibits tumor growth

CCR8, Tregs, mAbs, humanized

Yosuke Tanaka, et al.

2022

Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors

CML, leukemia stem cells, IRAK1/4 inhibitors, PD-L1, combined therapy

Bhavna Verma, et al.

2020

2D ex vivo patient derived acute myeloid leukemia platform for evaluation of novel molecular targeted therapeutic agents

AML, PDX

Srinivas Reddy Boreddy, et al.

2021

Development of BCA101, a Bifunctional Antibody Capable of Simultaneously Disabling EGFR and TGF-β Signaling, as a Novel Single-agent Immunotherapy

EGFR, TGF-β,antibody, prostate cancer, CDX, humanized

Srimoyee Ghosh, et al.

2019

TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo

LAG-3, mAb, PD-1, non-small lung carcinoma, HSCs, humanized

Roberto Vendramin, et al.

2021

Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma

melanoma, PDX

Ngoc Tung Tran, et al.

2020

CRISPR-Cas9-Mediated ELANE Mutation Correction in Hematopoietic Stem and Progenitor Cells to Treat Severe Congenital Neutropenia.

severe congenital neutropenia (SCN),neutrophils, HSPCs, humanized

Justin Cidado, et al.

2020

AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells.

CDK9 inhibitor, MCL-1, hematologic cancer, AML, PDX

Sujatha Kumar, et al.

2021

Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models

immune checkpoint, PD-1, mAbs,lung carcinoma, breast cancer, HSCs,CDX

Guixiang Dai, et al.

2021

Toward a humanized mouse model of pneumcystis pneumonia

epidemiology, Pneumocystis pneumonia, IgM, HSCs

Janell R. Richardson, et al.

2021

Defining Variation within a Next Gen Humanized Immune System Mouse Model of Human Lung Cancer in the Context of a Checkpoint Inhibitor Efficacy Study

HSCs, non-small cell lung cancer, small cell lung cancer, CDX, PDX

Ryoji Ito, et al.

2020

Bovine β-lactoglobulin-induced passive systemic anaphylaxis model using humanized NOG hIL-3/hGM-CSF transgenic mice

basophil, mast cell, milk allergy, PSA model, HSCs, humanized

Ilona-Petra Maser, et al.

2020

The Tumor Milieu Promotes Functional Human Tumor-Resident Plasmacytoid Dendritic Cells in Humanized Mouse Models.

Plasmacytoid dendritic cells (pDC), ovarian cancer, breast cancer, CDX, HSCs, humanized

Bhavna Verma, et al.

2020

Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents

HSCs, humanized, protocol

Zebin Wang, et al.

2019

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

PARP inhibitor, anti-PD-1, combined therapy, breast cancer, HSCs, humanized

Federico perdomo-Celis, et al.

2019

HIV Replication in Humanized IL-3/GM-CSF-Transgenic NOG Mice

HIV,humanized

James L. Weaver, et al.

2019

BLT-Immune Humanized Mice as a Model for Nivolumab-Induced Immune-Mediated Adverse Events: Comparison of the NOG and NOG-EXL Strains

BLT-immune humanized mice, anti-PD-1 mAbs

Srimoyee Ghosh, et al.

2018

Characterization of tumor growth and immune microenvironment in humanized NOG-EXL mice implanted with A549, MDA-MB-436 and A375 cells

HSCs,CDX, lung carcinoma, breast cancer, melanoma

Ryoji Ito, et al.

2018

A humanized mouse model to study asthmatic airway inflammation via the human IL-33/IL-13 axis

asthma, asthmatic airway inflammation, HSCs, humanized

Ryoji Ito, et al.

2017

A novel in vivo model for predicting myelotoxicity of chemotherapeutic agents using IL-3/GM-CSF transgenic humanized mice.

myelotoxicity, anti-cancer drugs

Ryoji Ito, et al.

2013

Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice.

myeloid cells, allergy, PCA reactions, HSCs, humanized